Tumor News and Research

RSS

Beta blocker use linked to NSCLC patient survival

Beta blockers may boost survival in patients undergoing definitive radiotherapy for non-small-cell lung cancer, suggests research published in the Annals of Oncology.

14 Jan 2013

Human papillomavirus an etiologic factor in 6% of OCSCC cases

High-risk human papillomavirus is an etiologic factor in approximately 6% of cases of oral cavity squamous cell carcinoma, according to epidemiologic research.

14 Jan 2013

Intermittent therapy may be answer to treating drug-resistant melanoma

Findings from a study carried out in mice suggest that an intermittent dosing strategy may be the answer to combating lethal tumor resistance to the BRAF inhibitor vemurafenib, in patients with late-stage BRAF-mutated melanoma.

14 Jan 2013

‘PapGene’ test detects endometrial and ovarian cancers

Researchers have adapted the papanicolaou smear test currently used to detect cervical cancer so that it can be used to screen women for endometrial and ovarian cancers.

14 Jan 2013

BGI-Shenzhen, CHOP to collaborate on research into pediatric brain tumors

The Children's Hospital of Philadelphia (CHOP) and BGI-Shenzhen today announced a formal agreement to collaborate on research into next-generation sequencing and analysis of pediatric brain tumors, in support of the Childhood Brain Tumor Tissue Consortium (CBTTC).

11 Jan 2013

Cancer researchers solve mystery of how Chd5 protein exerts its beneficial effects

A team of cancer researchers at Cold Spring Harbor Laboratory (CSHL) has solved the mystery of how one of the most powerful of the body's natural tumor-suppressing proteins, called Chd5, exerts its beneficial effects.

11 Jan 2013

Melanomas that develop resistance to vemurafenib also become addicted to the drug

Researchers in California and Switzerland have discovered that melanomas that develop resistance to the anti-cancer drug vemurafenib (marketed as Zelboraf), also develop addiction to the drug, an observation that may have important implications for the lives of patients with late-stage disease.

11 Jan 2013

DESI technique identifies cancer type, grade and tumor margins in brain surgery patients

A new tool that could allow for faster, more comprehensive testing of brain tissue during surgery successfully identified the cancer type, grade and tumor margins in five brain surgery patients, according to a Purdue University and Brigham and Women's Hospital study.

11 Jan 2013

New guidelines to help fast track radiation oncology drug development

Researchers from the translational research program of the National Cancer Institute and the Radiation Therapy Oncology Therapy Group have developed new guidelines to help fast track the clinical development of targeted cancer drugs in combination with radiation therapy.

11 Jan 2013

Research: Smaller radiation fields can effectively treat aggressive brain tumors

New research from Wake Forest Baptist Medical Center shows that patients suffering from aggressive brain tumors can be effectively treated with smaller radiation fields to spare the rest of the brain and preserve cognition.

11 Jan 2013

Scientists develop playbook to end devastating impact of fibrotic diseases

A team of scientists has developed a playbook for ending the devastating impact of fibrotic diseases of the liver, lung, kidney, and other organs, which are responsible for as many as 45 percent of all deaths in the industrialized world.

11 Jan 2013

Mutation that causes sickle cell anemia may offer new way to treat drug-resistant cancers

The genetic mutation that causes sickle cell anemia also turns red blood cells into potent tumor killers and may offer a new way to treat cancers that are resistant to existing treatments, according to research published January 9, 2013 in the open access journal PLOS ONE by David S. Terman of Jenomic Research Institute and colleagues from Duke University and other institutions.

10 Jan 2013

High-fiber diets may control progression of prostate cancer

A high-fiber diet may have the clinical potential to control the progression of prostate cancer in patients diagnosed in early stages of the disease.

10 Jan 2013

Oxaliplatin and bevacizumab disappoint for rectal cancer

The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results.

9 Jan 2013

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional PV-10 injection of melanoma tumors.

9 Jan 2013

Combination of pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer

A combination of the drugs pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer (ATC), according to a Mayo Clinic-led study published in the journal Science Translational Medicine.

9 Jan 2013

Key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis

Researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis. The study, which paves the way for developing novel targeted ovarian cancer therapies, is published online in the current issue of Cell Cycle.

9 Jan 2013

Insect research yields insights for muscle control and nerve disorders in mammals

Working with fruit flies, Johns Hopkins scientists have decoded the activity of protein signals that let certain nerve cells know when and where to branch so that they reach and connect to their correct muscle targets. The proteins' mammalian counterparts are known to have signaling roles in immunity, nervous system and heart development, and tumor progression, suggesting broad implications for human disease research.

9 Jan 2013

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2013 recipients of the Damon Runyon-Rachleff Innovation Award.

8 Jan 2013

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody program to enter the clinic in just three years from initiation of discovery.

7 Jan 2013

Tumor News and Research

Beta blocker use linked to NSCLC patient survival

Human papillomavirus an etiologic factor in 6% of OCSCC cases

Intermittent therapy may be answer to treating drug-resistant melanoma

‘PapGene’ test detects endometrial and ovarian cancers

BGI-Shenzhen, CHOP to collaborate on research into pediatric brain tumors

Cancer researchers solve mystery of how Chd5 protein exerts its beneficial effects

Melanomas that develop resistance to vemurafenib also become addicted to the drug

DESI technique identifies cancer type, grade and tumor margins in brain surgery patients

New guidelines to help fast track radiation oncology drug development

Research: Smaller radiation fields can effectively treat aggressive brain tumors

Scientists develop playbook to end devastating impact of fibrotic diseases

Mutation that causes sickle cell anemia may offer new way to treat drug-resistant cancers

High-fiber diets may control progression of prostate cancer

Oxaliplatin and bevacizumab disappoint for rectal cancer

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Combination of pazopanib and paclitaxel shows promise in slowing anaplastic thyroid cancer

Key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis

Insect research yields insights for muscle control and nerve disorders in mammals

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

arGEN-X commences ARGX-110 Phase Ib trial to treat cancer

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News